Serum neurofilament light chain, cognition and neuropsychiatric symptoms in multiple sclerosis

Takeaway

  • For multiple sclerosis (MS) patients with modest clinical manifestations and no acute disease activity, serum neurofilament light chain (sNfL) levels are not a surrogate biomarker for cognitive performance and neuropsychiatric symptoms.

Why this matters

    Traditional measures of MS disease activity and burden do not relate to cognitive and neuropsychiatric status, thus new biomarkers are needed to assess axonal tissue damage and potentially predict clinical outcomes.